Sagar Uday Nigwekar, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calciphylaxis | 36 | 2023 | 124 | 13.370 |
Why?
|
| Renal Dialysis | 30 | 2024 | 1786 | 4.150 |
Why?
|
| Kidney Failure, Chronic | 35 | 2023 | 2538 | 3.920 |
Why?
|
| Renal Insufficiency, Chronic | 21 | 2023 | 2208 | 3.140 |
Why?
|
| Thiosulfates | 9 | 2020 | 52 | 2.610 |
Why?
|
| Uremia | 5 | 2019 | 201 | 2.180 |
Why?
|
| Hyponatremia | 7 | 2023 | 298 | 2.040 |
Why?
|
| Nephrology | 5 | 2024 | 263 | 1.460 |
Why?
|
| Hyperparathyroidism, Secondary | 4 | 2019 | 126 | 1.390 |
Why?
|
| Acute Kidney Injury | 12 | 2022 | 1972 | 1.330 |
Why?
|
| Olfaction Disorders | 2 | 2022 | 222 | 1.180 |
Why?
|
| Anemia, Sickle Cell | 5 | 2021 | 1018 | 1.130 |
Why?
|
| Skin Diseases | 5 | 2020 | 1065 | 1.110 |
Why?
|
| Vitamin K | 2 | 2019 | 295 | 1.050 |
Why?
|
| Leg Ulcer | 2 | 2019 | 69 | 0.950 |
Why?
|
| Myelinolysis, Central Pontine | 1 | 2023 | 18 | 0.930 |
Why?
|
| Sickle Cell Trait | 3 | 2021 | 81 | 0.900 |
Why?
|
| Taste Disorders | 1 | 2022 | 41 | 0.820 |
Why?
|
| Hip Fractures | 4 | 2019 | 955 | 0.800 |
Why?
|
| Hyperphosphatemia | 2 | 2023 | 40 | 0.760 |
Why?
|
| Dialysis Solutions | 1 | 2019 | 39 | 0.700 |
Why?
|
| Sodium | 3 | 2023 | 1623 | 0.700 |
Why?
|
| Parathyroidectomy | 3 | 2019 | 235 | 0.690 |
Why?
|
| Vitamin K Deficiency | 1 | 2019 | 24 | 0.680 |
Why?
|
| Arterioles | 2 | 2016 | 254 | 0.640 |
Why?
|
| Hyperhomocysteinemia | 2 | 2016 | 124 | 0.630 |
Why?
|
| Ergocalciferols | 3 | 2015 | 110 | 0.630 |
Why?
|
| Kidney Diseases | 10 | 2018 | 2149 | 0.630 |
Why?
|
| Chelating Agents | 3 | 2020 | 380 | 0.620 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2009 | 393 | 0.620 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2009 | 194 | 0.610 |
Why?
|
| Skin | 5 | 2020 | 4364 | 0.600 |
Why?
|
| Vitamin B Complex | 2 | 2016 | 288 | 0.580 |
Why?
|
| Carboxylic Acids | 1 | 2017 | 97 | 0.570 |
Why?
|
| Hypotension | 1 | 2022 | 884 | 0.550 |
Why?
|
| Potassium | 1 | 2019 | 1336 | 0.520 |
Why?
|
| Folic Acid | 3 | 2016 | 1300 | 0.490 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2014 | 87 | 0.480 |
Why?
|
| Humans | 120 | 2023 | 744343 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2020 | 9959 | 0.470 |
Why?
|
| Hospitalists | 2 | 2008 | 305 | 0.460 |
Why?
|
| Referral and Consultation | 6 | 2018 | 3528 | 0.440 |
Why?
|
| Skin Diseases, Vascular | 1 | 2013 | 39 | 0.430 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 849 | 0.420 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2017 | 838 | 0.420 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2016 | 417 | 0.410 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 1081 | 0.410 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 1073 | 0.400 |
Why?
|
| Natriuretic Peptides | 2 | 2011 | 150 | 0.400 |
Why?
|
| Middle Aged | 48 | 2023 | 213383 | 0.380 |
Why?
|
| Dietary Supplements | 5 | 2022 | 3297 | 0.370 |
Why?
|
| Thyroid Hormones | 1 | 2013 | 390 | 0.370 |
Why?
|
| Bone Density Conservation Agents | 4 | 2022 | 773 | 0.350 |
Why?
|
| Osteoporosis | 4 | 2020 | 1580 | 0.350 |
Why?
|
| Rare Diseases | 1 | 2014 | 553 | 0.350 |
Why?
|
| Kidney Transplantation | 4 | 2019 | 4251 | 0.340 |
Why?
|
| Vitamin D Deficiency | 3 | 2015 | 1343 | 0.340 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2009 | 63 | 0.340 |
Why?
|
| Male | 56 | 2023 | 350118 | 0.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2014 | 3255 | 0.330 |
Why?
|
| Warfarin | 5 | 2023 | 1496 | 0.320 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2008 | 160 | 0.320 |
Why?
|
| Diuretics | 1 | 2011 | 592 | 0.320 |
Why?
|
| Premedication | 1 | 2009 | 258 | 0.310 |
Why?
|
| Acetylcysteine | 1 | 2009 | 272 | 0.300 |
Why?
|
| Female | 57 | 2023 | 380194 | 0.300 |
Why?
|
| Hydrothorax | 1 | 2006 | 16 | 0.290 |
Why?
|
| Vitamin D | 4 | 2016 | 3223 | 0.290 |
Why?
|
| Aged | 36 | 2023 | 163280 | 0.280 |
Why?
|
| Metabolic Diseases | 1 | 2013 | 658 | 0.280 |
Why?
|
| Natural Language Processing | 1 | 2014 | 1041 | 0.280 |
Why?
|
| Biopsy | 4 | 2020 | 6756 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 8 | 2023 | 2170 | 0.270 |
Why?
|
| Risk Factors | 19 | 2021 | 72290 | 0.270 |
Why?
|
| Atrial Fibrillation | 3 | 2018 | 5034 | 0.270 |
Why?
|
| Cause of Death | 7 | 2020 | 3584 | 0.260 |
Why?
|
| Gastric Bypass | 1 | 2014 | 812 | 0.260 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2005 | 58 | 0.260 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 277 | 0.250 |
Why?
|
| Diphosphonates | 2 | 2019 | 623 | 0.250 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 3674 | 0.250 |
Why?
|
| Polycythemia Vera | 1 | 2006 | 164 | 0.240 |
Why?
|
| Cardiovascular Diseases | 10 | 2022 | 15165 | 0.240 |
Why?
|
| Pyridones | 2 | 2018 | 712 | 0.230 |
Why?
|
| Inservice Training | 1 | 2006 | 392 | 0.230 |
Why?
|
| Metronidazole | 1 | 2004 | 217 | 0.230 |
Why?
|
| Length of Stay | 4 | 2013 | 6309 | 0.230 |
Why?
|
| Vascular Diseases | 2 | 2022 | 1161 | 0.230 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 1213 | 0.220 |
Why?
|
| Renal Artery | 1 | 2005 | 398 | 0.220 |
Why?
|
| Hypercalcemia | 2 | 2023 | 409 | 0.220 |
Why?
|
| Muscle Cramp | 1 | 2022 | 35 | 0.220 |
Why?
|
| Rickets | 1 | 2023 | 74 | 0.210 |
Why?
|
| Bone Density | 3 | 2020 | 3468 | 0.210 |
Why?
|
| Hypophosphatemia | 1 | 2023 | 85 | 0.210 |
Why?
|
| Homocysteine | 2 | 2016 | 647 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2018 | 7729 | 0.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2018 | 1518 | 0.210 |
Why?
|
| Fanconi Syndrome | 1 | 2022 | 35 | 0.210 |
Why?
|
| Postoperative Complications | 4 | 2014 | 15295 | 0.200 |
Why?
|
| International Classification of Diseases | 2 | 2019 | 867 | 0.200 |
Why?
|
| Hospitalization | 2 | 2021 | 10262 | 0.200 |
Why?
|
| Wound Healing | 2 | 2015 | 2785 | 0.200 |
Why?
|
| Case-Control Studies | 7 | 2021 | 21746 | 0.200 |
Why?
|
| Carnitine | 1 | 2022 | 246 | 0.190 |
Why?
|
| Venous Thrombosis | 3 | 2018 | 1239 | 0.190 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 66 | 0.190 |
Why?
|
| Anticoagulants | 4 | 2019 | 4599 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 1 | 2006 | 665 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 12959 | 0.180 |
Why?
|
| Smell | 1 | 2022 | 244 | 0.180 |
Why?
|
| Adult | 26 | 2023 | 214055 | 0.180 |
Why?
|
| Malnutrition | 2 | 2017 | 625 | 0.180 |
Why?
|
| Liver Cirrhosis | 2 | 2021 | 1863 | 0.180 |
Why?
|
| Cohort Studies | 11 | 2023 | 40561 | 0.180 |
Why?
|
| Fatal Outcome | 2 | 2015 | 1850 | 0.180 |
Why?
|
| Physician's Role | 1 | 2007 | 943 | 0.180 |
Why?
|
| Serum Albumin | 1 | 2023 | 676 | 0.180 |
Why?
|
| Blood Substitutes | 1 | 2019 | 58 | 0.180 |
Why?
|
| Abdominal Pain | 1 | 2006 | 1063 | 0.170 |
Why?
|
| Carbon-Carbon Ligases | 1 | 2019 | 20 | 0.170 |
Why?
|
| Internal Medicine | 1 | 2006 | 1009 | 0.170 |
Why?
|
| Retrospective Studies | 21 | 2023 | 77449 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 275 | 0.160 |
Why?
|
| Vitamin K 1 | 1 | 2018 | 48 | 0.160 |
Why?
|
| Renal Replacement Therapy | 3 | 2010 | 257 | 0.160 |
Why?
|
| Prognosis | 9 | 2021 | 29063 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2018 | 1972 | 0.160 |
Why?
|
| Alanine | 1 | 2020 | 572 | 0.160 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2019 | 163 | 0.150 |
Why?
|
| Angiopoietin-2 | 1 | 2019 | 173 | 0.150 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2021 | 386 | 0.150 |
Why?
|
| Pancreatitis | 1 | 2004 | 1092 | 0.150 |
Why?
|
| Teriparatide | 1 | 2019 | 225 | 0.150 |
Why?
|
| Theophylline | 1 | 2017 | 132 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2018 | 290 | 0.150 |
Why?
|
| Bone and Bones | 2 | 2019 | 2575 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2022 | 1504 | 0.140 |
Why?
|
| Peritoneal Dialysis | 1 | 2017 | 146 | 0.140 |
Why?
|
| Professional Practice | 1 | 2019 | 326 | 0.140 |
Why?
|
| Fractures, Bone | 2 | 2021 | 1947 | 0.140 |
Why?
|
| General Practice | 1 | 2017 | 100 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2017 | 215 | 0.140 |
Why?
|
| Absorptiometry, Photon | 2 | 2019 | 1725 | 0.140 |
Why?
|
| Apatites | 1 | 2015 | 19 | 0.140 |
Why?
|
| Cholesterol | 5 | 2014 | 2917 | 0.130 |
Why?
|
| Debridement | 1 | 2018 | 492 | 0.130 |
Why?
|
| Thrombophilia | 1 | 2018 | 305 | 0.130 |
Why?
|
| Triglycerides | 4 | 2014 | 2454 | 0.130 |
Why?
|
| Vitamin B 6 | 1 | 2016 | 237 | 0.130 |
Why?
|
| Necrosis | 1 | 2019 | 1643 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2309 | 0.130 |
Why?
|
| Histone Deacetylases | 1 | 2019 | 728 | 0.130 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 307 | 0.120 |
Why?
|
| Albuminuria | 1 | 2018 | 682 | 0.120 |
Why?
|
| Massachusetts | 4 | 2020 | 8663 | 0.120 |
Why?
|
| Muscle Contraction | 1 | 2019 | 1240 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2017 | 23403 | 0.120 |
Why?
|
| Electrolytes | 1 | 2015 | 282 | 0.120 |
Why?
|
| Risk Assessment | 9 | 2021 | 23338 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 57776 | 0.120 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 1465 | 0.120 |
Why?
|
| Calcium | 2 | 2018 | 5756 | 0.120 |
Why?
|
| Algorithms | 1 | 2014 | 13881 | 0.120 |
Why?
|
| Microvessels | 1 | 2018 | 544 | 0.120 |
Why?
|
| Time Factors | 9 | 2019 | 40075 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2006 | 2303 | 0.120 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 952 | 0.110 |
Why?
|
| Leg | 1 | 2019 | 1116 | 0.110 |
Why?
|
| Chronic Disease | 5 | 2019 | 9146 | 0.110 |
Why?
|
| Anemia | 1 | 2023 | 1506 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2015 | 247 | 0.110 |
Why?
|
| Vitamin B 12 | 1 | 2016 | 527 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1102 | 0.110 |
Why?
|
| Self Care | 1 | 2018 | 786 | 0.110 |
Why?
|
| Parathyroid Hormone | 2 | 2017 | 1801 | 0.110 |
Why?
|
| Nutritional Status | 2 | 2019 | 1609 | 0.110 |
Why?
|
| Comorbidity | 6 | 2020 | 10388 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 2031 | 0.110 |
Why?
|
| Fenoldopam | 1 | 2011 | 8 | 0.100 |
Why?
|
| Diuretics, Osmotic | 1 | 2011 | 37 | 0.100 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2011 | 76 | 0.100 |
Why?
|
| Minerals | 1 | 2013 | 275 | 0.100 |
Why?
|
| Medication Adherence | 2 | 2020 | 2063 | 0.100 |
Why?
|
| Calcifediol | 1 | 2012 | 166 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2007 | 4558 | 0.100 |
Why?
|
| Prevalence | 3 | 2022 | 15226 | 0.100 |
Why?
|
| Age of Onset | 1 | 2018 | 3271 | 0.100 |
Why?
|
| Perioperative Care | 2 | 2009 | 1002 | 0.100 |
Why?
|
| Remission Induction | 2 | 2013 | 2386 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2011 | 135 | 0.090 |
Why?
|
| Hypertension | 2 | 2022 | 8480 | 0.090 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 4258 | 0.090 |
Why?
|
| Fibroblast Growth Factors | 1 | 2016 | 879 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2017 | 5317 | 0.090 |
Why?
|
| Treatment Outcome | 12 | 2019 | 63114 | 0.090 |
Why?
|
| Incidence | 3 | 2018 | 20947 | 0.090 |
Why?
|
| Proteinuria | 2 | 2009 | 658 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 6364 | 0.080 |
Why?
|
| Protein S Deficiency | 1 | 2008 | 16 | 0.080 |
Why?
|
| Protein C Deficiency | 1 | 2008 | 29 | 0.080 |
Why?
|
| Acute Disease | 2 | 2009 | 7149 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 789 | 0.080 |
Why?
|
| Shock, Septic | 1 | 2015 | 775 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 3023 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2278 | 0.080 |
Why?
|
| Kidney | 3 | 2022 | 7186 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2015 | 984 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 15076 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2009 | 9849 | 0.080 |
Why?
|
| New York | 2 | 2007 | 886 | 0.070 |
Why?
|
| Cholecalciferol | 1 | 2012 | 537 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 19905 | 0.070 |
Why?
|
| Terminal Care | 1 | 2018 | 1694 | 0.070 |
Why?
|
| ROC Curve | 1 | 2014 | 3527 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3508 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2017 | 8436 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2006 | 5788 | 0.070 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2008 | 161 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 451 | 0.070 |
Why?
|
| Splenomegaly | 1 | 2006 | 190 | 0.070 |
Why?
|
| Physicians, Family | 1 | 2007 | 345 | 0.060 |
Why?
|
| Connective Tissue Diseases | 1 | 2008 | 264 | 0.060 |
Why?
|
| United States | 5 | 2021 | 69872 | 0.060 |
Why?
|
| Registries | 2 | 2018 | 8089 | 0.060 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2004 | 30 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2007 | 426 | 0.060 |
Why?
|
| Disease Progression | 5 | 2023 | 13284 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2021 | 10252 | 0.060 |
Why?
|
| Thrombosis | 1 | 2018 | 2968 | 0.060 |
Why?
|
| Risk | 1 | 2017 | 9687 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5751 | 0.060 |
Why?
|
| Research Design | 1 | 2020 | 5987 | 0.060 |
Why?
|
| Aldosterone | 1 | 2009 | 877 | 0.060 |
Why?
|
| Palliative Care | 1 | 2018 | 3493 | 0.060 |
Why?
|
| Diabetic Foot | 1 | 2007 | 355 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7913 | 0.060 |
Why?
|
| Respiration, Artificial | 2 | 2018 | 2569 | 0.060 |
Why?
|
| Thoracic Surgery | 1 | 2010 | 719 | 0.060 |
Why?
|
| Portal Vein | 1 | 2006 | 437 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2019 | 3445 | 0.060 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 2759 | 0.060 |
Why?
|
| Vaginosis, Bacterial | 1 | 2004 | 128 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2009 | 924 | 0.060 |
Why?
|
| Creatinine | 1 | 2009 | 1919 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 840 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8642 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2009 | 2971 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2009 | 2618 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2018 | 8554 | 0.050 |
Why?
|
| Hospitals, General | 1 | 2006 | 749 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| China | 2 | 2018 | 2248 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 4933 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2009 | 849 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 537 | 0.050 |
Why?
|
| Calcitriol | 1 | 2023 | 298 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 66 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2009 | 1167 | 0.050 |
Why?
|
| Bicarbonates | 1 | 2022 | 313 | 0.050 |
Why?
|
| Glucose | 1 | 2013 | 4397 | 0.050 |
Why?
|
| Hepatorenal Syndrome | 1 | 2021 | 61 | 0.050 |
Why?
|
| Age Factors | 3 | 2018 | 18370 | 0.050 |
Why?
|
| India | 1 | 2006 | 2197 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14722 | 0.040 |
Why?
|
| Myocardial Infarction | 3 | 2016 | 11727 | 0.040 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 2 | 2009 | 29 | 0.040 |
Why?
|
| Angiography | 1 | 2005 | 1639 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2019 | 122 | 0.040 |
Why?
|
| Phosphates | 1 | 2023 | 786 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2018 | 3913 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 1855 | 0.040 |
Why?
|
| Penis | 1 | 2020 | 216 | 0.040 |
Why?
|
| Neoplasms | 3 | 2022 | 21683 | 0.040 |
Why?
|
| Rats | 1 | 2015 | 24260 | 0.040 |
Why?
|
| Animals | 4 | 2019 | 168757 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2021 | 53288 | 0.040 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2022 | 687 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12354 | 0.040 |
Why?
|
| Hip | 1 | 2019 | 257 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2018 | 69 | 0.040 |
Why?
|
| Femur Neck | 1 | 2019 | 309 | 0.040 |
Why?
|
| Survival Rate | 3 | 2020 | 12788 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17446 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 1420 | 0.040 |
Why?
|
| Heart Rate | 1 | 2009 | 4091 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2018 | 588 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2004 | 1257 | 0.040 |
Why?
|
| Quality of Life | 1 | 2018 | 12804 | 0.040 |
Why?
|
| Stroke | 2 | 2018 | 9981 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 840 | 0.040 |
Why?
|
| Hyperkalemia | 2 | 2009 | 218 | 0.040 |
Why?
|
| Hypolipidemic Agents | 2 | 2014 | 604 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 281 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2022 | 1185 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 236 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 3610 | 0.040 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2018 | 287 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2018 | 3461 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2018 | 281 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 498 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 18029 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 2019 | 575 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 499 | 0.030 |
Why?
|
| Amino Acids | 1 | 2022 | 1736 | 0.030 |
Why?
|
| Metagenomics | 1 | 2019 | 428 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8324 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 684 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 954 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2009 | 3864 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2018 | 642 | 0.030 |
Why?
|
| Radiography | 1 | 2006 | 7023 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2007 | 3313 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 25043 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2009 | 5102 | 0.030 |
Why?
|
| Sepsis | 1 | 2008 | 2593 | 0.030 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 401 | 0.030 |
Why?
|
| Sex Factors | 2 | 2018 | 10397 | 0.030 |
Why?
|
| Curriculum | 1 | 2006 | 3605 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 85781 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 763 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 2959 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2018 | 648 | 0.030 |
Why?
|
| Recurrence | 1 | 2004 | 8340 | 0.030 |
Why?
|
| Obesity | 1 | 2015 | 12745 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2013 | 276 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 956 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1641 | 0.030 |
Why?
|
| Spine | 1 | 2019 | 1144 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2022 | 1859 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 13989 | 0.030 |
Why?
|
| New England | 1 | 2015 | 1022 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2749 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 2061 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 1118 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2015 | 1100 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2006 | 4687 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 980 | 0.020 |
Why?
|
| Reference Values | 1 | 2018 | 4982 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 15540 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2018 | 1158 | 0.020 |
Why?
|
| Dopamine Agents | 1 | 2010 | 189 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2009 | 110 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 2046 | 0.020 |
Why?
|
| Graft Rejection | 2 | 2014 | 4397 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 2987 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2019 | 2119 | 0.020 |
Why?
|
| Inpatients | 1 | 2018 | 2518 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 977 | 0.020 |
Why?
|
| Boston | 1 | 2018 | 9313 | 0.020 |
Why?
|
| Inflammation | 2 | 2017 | 10638 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 14557 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 2009 | 759 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 39050 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11366 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 3923 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 10900 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 11725 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4468 | 0.010 |
Why?
|
| Child | 2 | 2023 | 77709 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2011 | 1373 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 2009 | 1504 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16365 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
| Young Adult | 2 | 2018 | 56430 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2015 | 12026 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12261 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15519 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 6489 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 6459 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2010 | 2788 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 35136 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 41006 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 12245 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 81183 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 26385 | 0.000 |
Why?
|